Project: Anti-biofilm therapies using local application of bacteriophages

Acronym ANTIBIO-LAB (Reference Number: JPIAMR_2018_P001)
Duration 01/01/2019 - 31/12/2021
Project Topic The use of medical devices has had an enormously positive impact on patient care. However, approximately 5% of patients across all medical specialities can develop an infection associated with the device, which can have disastrous consequences. These bacterial infections involve biofilm formation and are therefore always highly antibiotic tolerant, even in the absence of specific antibiotic resistance genes. The antibiotic recalcitrance of the biofilm leads to poor treatment success rates and often requires implant removal to treat the infection. The ANTIBIO-LAB consortium's overall aim is to introduce a new concept in the treatment of antibiotic resistant biofilm infections by delivering biofilmadapted bacteriophages in a customised local delivery vehicle. The methods that we will employ draw from our collective experience in phage isolation, phage in vitro evolution, local delivery vehicle design, and clinically relevant in vitro and in vivo models of biofilm infection.
Website visit project website
Network JPI AMR
Call 6th Joint Call of JPIAMR

Project partner

Number Name Role Country
1 AO Research Institute Davos Coordinator Switzerland
2 Universitätsmedizin Berlin Partner Germany
3 University Hospitals Leuven Partner Belgium
4 AO Research Institute Davos Partner Switzerland
5 Université Catholique de Louvain Observer Belgium
6 PRO-IMPLANT Foundation Observer Germany